Ligand Pharmaceuticals Incorporated (LGNZZ)

OTCMKTS · Delayed Price · Currency is USD
0.0700
-0.0020 (-2.78%)
At close: Jan 14, 2026
Market Cap3.68B +66.1%
Revenue (ttm)251.23M +64.8%
Net Income48.58M +7.4%
EPS2.49 +0.8%
Shares Outn/a
PE Ratio75.77
Forward PE22.68
Dividendn/a
Ex-Dividend Daten/a
Volume3,065
Average Volume4,804
Open0.0700
Previous Close0.0720
Day's Range0.0700 - 0.0700
52-Week Range0.0676 - 0.1400
Beta1.04
RSI40.60
Earnings DateFeb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1987
Employees 68
Stock Exchange OTCMKTS
Ticker Symbol LGNZZ
Full Company Profile

Financial Performance

Financial Statements